Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and : Lilly, Incyte COVID-19 Drug Fails To Meet Primary Endpoint

04/08/2021 | 07:04am EDT


ę MT Newswires 2021
All news about ELI LILLY AND COMPANY
01:32pCompanies Ponder Speeding Up Plans to Bring Workers Back to Offices -- Update
DJ
10:28aCompanies Ponder Speeding Up Plans to Bring Workers Back to Offices
DJ
05/13Samsung BioLogics says decision pending on making Moderna vaccine as report i..
RE
05/13TORRENT PHARMACEUTICALSá : Signs Licensing Agreement with Eli Lilly for COVID-19..
MT
05/13ELI LILLY ANDá : Lilly to Participate in UBS Global Healthcare Virtual Conferenc..
PR
05/13Push for Covid-19 Vaccine Patent Waiver Isn't a Panacea - but It Could Nudge ..
AQ
05/13ELI LILLY AND COMPANY : Ex-dividend day for
FA
05/11ELI LILLY ANDá : MiNA Therapeutics Launch Research Collaboration
MT
05/11ELI LILLY ANDá : Lilly Starts Global Research Collaboration With MiNA Therapeuti..
MT
05/11ELI LILLY ANDá : Lilly and MiNA Therapeutics Announce saRNA Research Collaborati..
PR
More news
Financials (USD)
Sales 2021 27 323 M - -
Net income 2021 6 776 M - -
Net Debt 2021 11 229 M - -
P/E ratio 2021 26,7x
Yield 2021 1,70%
Capitalization 178 B 178 B -
EV / Sales 2021 6,94x
EV / Sales 2022 6,74x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 216,04 $
Last Close Price 196,21 $
Spread / Highest target 29,5%
Spread / Average Target 10,1%
Spread / Lowest Target -10,8%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Senior VP, Chief Information & Digital Officer
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY16.21%178 360
JOHNSON & JOHNSON8.16%448 257
ROCHE HOLDING AG-1.80%290 657
PFIZER, INC.8.94%224 020
ABBVIE INC.8.66%205 641
NOVARTIS AG-3.78%200 099